quiescent leukaemia stem cells
AML leukemic stem cells
cancer stem cells
human AMLs
Immuno-targeting of human AML quiescent cells
leukaemia maintenance
leukemic stem cell-specific human recombinant antibodies
validation of human recombinant antibodies
novel therapeutic antibodies
development of candidate antibodies
Acute Myeloid Leukaemia
treatment of AMLs
novel phage display approach
use of phage display technology
innovative phage-display antibody screening platform
relative impact of quiescent
relapse
chemotherapy
exploitation activities
ERC Advanced Grant project
business development
proliferative CSCs
disease remission
innovative mouse xenotransplantation model
NGS-based antibody selection procedure
market
intellectual property management
competition analyses
product
real fuel
results
main objective
tumour growth
InMec
cheap identification
onset
promotion of commercial
hypothesis
primary goal
fatal hematologic malignancy
knowledge unprecedented
patients
treatments
majority of patient
partner TTFactor